Untreated, unresectable mCRC considered suitable for capecitabine monotherapy (n = 471)

Randomised (n = 471)

Capecitabine (n = 156)
Capecitabine, Bevacizumab (n = 157)
Capecitabine, Bevacizumab, Mitomycin C (n = 158)

Randomly selected tumor specimens for IHC and CNV concordance assessment (n = 59)

CNV = copy number variation, IHC = immunohistochemistry, mCRC = metastatic colorectal cancer